BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37919058)

  • 1.
    Zheng Y; Zhang Z; Li X; Wu L; Liu X; Liu L; Chen J; Wei D
    Front Biosci (Landmark Ed); 2023 Oct; 28(10):257. PubMed ID: 37919058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LINC01572 promotes the malignant progression of lung adenocarcinoma by modulating p53 mediated by miRNA-338-5p/TTK axis.
    Liu S; Liu X; Yang Q; Zeng C; Hu G; Ren B
    J Pharm Pharmacol; 2024 May; ():. PubMed ID: 38698658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a ferroptosis scoring system and identification of LINC01572 as a novel ferroptosis suppressor in lung adenocarcinoma.
    Hong L; Wang X; Cui W; Wang F; Shi W; Yu S; Luo Y; Zhong L; Zhao X
    Front Pharmacol; 2022; 13():1098136. PubMed ID: 36686701
    [No Abstract]   [Full Text] [Related]  

  • 4. Overexpression of lncRNA A2M-AS1 inhibits cell growth and aggressiveness
    Guo H; Li T; Peng C; Mao Q; Shen B; Shi M; Lu H; Xiao T; Yang A; Liu Y
    Hum Exp Toxicol; 2022; 41():9603271221138971. PubMed ID: 36461613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
    Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
    PeerJ; 2023; 11():e16166. PubMed ID: 37790630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LINC02535/miR-30a-5p/GALNT3 axis contributes to lung adenocarcinoma progression via the NF- κ B signaling pathway.
    Li Y; Zhao J; Zhang W; Wang A; Jiao M; Cai X; Zhu J; Liu Z; Huang JA
    Cell Cycle; 2022 Dec; 21(23):2455-2470. PubMed ID: 35852407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma.
    Liu T; Zhu J; Du W; Ning W; Zhang Y; Zeng Y; Liu Z; Huang JA
    Respir Res; 2020 Sep; 21(1):227. PubMed ID: 32873299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA
    Hao X; Zhang M; Gu M; Wang Z; Zhou S; Li W; Xu S
    PeerJ; 2022; 10():e13871. PubMed ID: 36032951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma.
    Hao XL; Tian Z; Han F; Chen JP; Gao LY; Liu JY
    Pathol Res Pract; 2019 Jul; 215(7):152438. PubMed ID: 31126818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
    Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
    Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of eIF6 as a prognostic factor that drives tumor progression and predicts arsenic trioxide efficacy in lung adenocarcinoma.
    Shen Y; Zhang R; Li X
    Mol Biol Rep; 2023 Feb; 50(2):1167-1180. PubMed ID: 36435920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-147b promotes lung adenocarcinoma cell aggressiveness through negatively regulating microfibril-associated glycoprotein 4 (MFAP4) and affects prognosis of lung adenocarcinoma patients.
    Feng YY; Liu CH; Xue Y; Chen YY; Wang YL; Wu XZ
    Gene; 2020 Mar; 730():144316. PubMed ID: 31884109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
    Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
    Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma.
    Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X
    Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of Immune Implication and Prognostic Value of
    Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
    Front Oncol; 2021; 11():798425. PubMed ID: 35047409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.